News
Diversified healthcare company CVS Health (NYSE:CVS) announced better-than-expected revenue in Q1 CY2025, with sales up 7% ...
GlobalData on MSN19h
Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapiesNovo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.
Investor's Business Daily on MSN22h
Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna SkyrocketingNovo Nordisk inked an obesity deal worth up to $2.2 billion on Wednesday, and sent shares of Septerna into the stratosphere.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback